Cargando…

Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells

PD0332991 (palbociclib/Ibrance(®)) is a cyclin-dependent kinase (CDK)4/6 inhibitor that has recently been approved for the treatment of estrogen receptor-positive advanced breast cancer. The present study investigated the antiproliferative effects of PD0332991 on gastric cancer (GC) cells and the un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Daguang, Sun, Yabin, Li, Wei, Ye, Fei, Zhang, Yang, Guo, Yuchen, Zhang, David Y., Suo, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846637/ https://www.ncbi.nlm.nih.gov/pubmed/29436583 http://dx.doi.org/10.3892/ijmm.2018.3460

Ejemplares similares

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Liu, Yu, et al.
Publicado: (2022)

Retracted: Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
por: Schröder, Lisette B. W., et al.
Publicado: (2015)

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
por: Bollard, Julien, et al.
Publicado: (2017)

PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
por: Barton, Kelly L., et al.
Publicado: (2013)

FAM117A Is a New Prognostic Marker of Lung Adenocarcinoma and Predicts Sensitivity to PD0332991
por: Wu, Chao, et al.
Publicado: (2022)

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors
por: Liu, Minghui, et al.
Publicado: (2016)

PD 0332991对人内皮细胞增殖和凋亡的作用
Publicado: (2018)

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
por: Liu, Minghui, et al.
Publicado: (2021)

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
por: Schwartz, G K, et al.
Publicado: (2011)

PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis
por: LI, CHUNSHENG, et al.
Publicado: (2014)

Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells
por: Kitada, Kunio, et al.
Publicado: (2019)

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
por: Finn, Richard S, et al.
Publicado: (2009)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

SAR study on N(2),N(4)-disubstituted pyrimidine-2,4-diamines as effective CDK2/CDK9 inhibitors and antiproliferative agents
por: Jing, Liandong, et al.
Publicado: (2018)

Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1
por: Noh, Ji-Yoon, et al.
Publicado: (2022)

Protein profiling of alpha-fetoprotein producing gastric adenocarcinoma
por: He, Liang, et al.
Publicado: (2016)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways
por: Li, Wei, et al.
Publicado: (2019)

Association of serum levels of deoxyribose 1-phosphate and S-lactoylglutathione with neoadjuvant chemotherapy sensitivity in patients with gastric cancer: A metabolomics study
por: Wang, Daguang, et al.
Publicado: (2020)

Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines
por: GU, MENGLI, et al.
Publicado: (2014)

Protein expression profiles and clinicopathologic characteristics associate with gastric cancer survival
por: Li, Wei, et al.
Publicado: (2019)

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023)

Poly[[diaquabis{μ-4-[6-(4-carboxyphenyl)-4,4′-bipyridin-2-yl]benzoato-κ(2) O:N (1′)}copper(II)] dimethylformamide tetrasolvate]
por: Sun, Yabin, et al.
Publicado: (2013)

Combining multi-dimensional data to identify key genes and pathways in gastric cancer
por: Ren, Wu, et al.
Publicado: (2017)

The Antiproliferative Effects of Flavonoid MAO Inhibitors on Prostate Cancer Cells
por: Zarmouh, Najla O., et al.
Publicado: (2020)

Synthesis and Biological Evaluation of Indole-2-Carboxamides with Potent Apoptotic Antiproliferative Activity as EGFR/CDK2 Dual Inhibitors
por: Al-Wahaibi, Lamya H., et al.
Publicado: (2022)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

Sulforaphane-cysteine downregulates CDK4 /CDK6 and inhibits tubulin polymerization contributing to cell cycle arrest and apoptosis in human glioblastoma cells
por: Li, Juntao, et al.
Publicado: (2020)

Serum metabolomic profiling of human gastric cancer and its relationship with the prognosis
por: Wang, Daguang, et al.
Publicado: (2017)

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
por: Menon, Malini, et al.
Publicado: (2019)

Colorectal cancer cells suppress CD4+ T cells immunity through canonical Wnt signaling
por: Sun, Xuan, et al.
Publicado: (2017)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

miR-449a and CDK6 in gastric carcinoma
por: LI, LI-PING, et al.
Publicado: (2014)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
por: Wu, Yanmei, et al.
Publicado: (2020)

Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer
por: Zhang, Jian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h0laf188b9b162k6b9v6ni3vmq